There are only two clinical-stage TRBAs currently targeting CD19, blinatumomab, which has been approved under the trade name Blincyto® for treatment of B cell acute lymphoblastic leukemia (B-ALL) and AMG 562, a half-life extended BiTE® construct in Phase I clinical trials [372]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.